Zydus Cadila has received final approval from the US health regulator for Piroxicam Capsules, used for treatment of osteoarthritis and rheumatoid arthritis.
Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Piroxicam Capsules USP in the strengths of 10 mg and 20 mg, the company said in a BSE filing.
Zydus Cadila said the drug will be produced at the group's manufacturing facility at SEZ, Ahmedabad.
The group has more than 209 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.
Shares of Cadila Healthcare, the listed entity of the group, were trading 1.52 down per cent at Rs 348.70 per scrip on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)